An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent
|ClinicalTrials.gov Identifier: NCT00002091|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
PRIMARY: To determine whether pentoxifylline changes the self-reported measures of quality of life status, using measures of scores from double-blinded drug withdrawal and drug restart periods.
SECONDARY: To measure the changes in monthly CD4 counts, fasting serum triglyceride levels, and weight; to assess the safety of pentoxifylline in HIV-infected persons.
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Pentoxifylline||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Official Title:||An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002091
|United States, Massachusetts|
|CRI of New England|
|Brookline, Massachusetts, United States, 02445|